Cortechs.ai | Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers

Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers

Study to determine the ability of clinically available volumetric MRI (vMRI) and CSF biomarkers, alone or in combination with a quantitative learning measure, to predict conversion to Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI). 2011 October 12.

[button]Download[/button]

More Resources

06/23/2026

Helping Our Clients Share Their Success Stories

Learn how Cortechs helps clients share clinical achievements, workflow improvements, and innovation through case studies, testimonials, webinars, and more.

06/15/2026

Alzheimer’s Awareness Month: Bringing Clarity to the Alzheimer’s Care Continuum Through Quantitative Imaging

Explore how quantitative imaging is helping clinicians assess, diagnose, and monitor Alzheimer’s disease and related dementias with greater clarity.

06/08/2026

Cortechs.ai and TAC Center Celebrate One Year of Advancing Neuroimaging Innovation in Peru

TAC Centers Peru is celebrating one year of integrating the NeuroQuant® suite into clinical practice.

06/04/2026

SNMMI 2026: Advancing the Future of Quantitative PET in Dementia Imaging

At SNMMI 2026, Cortechs.ai showcased NeuroQuant® PET and the growing role of quantitative PET imaging in dementia care.

06/02/2026

Cortechs.ai Collaborates with Microsoft to Bring AI-Powered Imaging Insights Directly into Radiology Workflows

Cortechs.ai and Microsoft are partnering to help bring advanced AI-powered quantitative imaging directly into radiology workflows.

05/26/2026

Cortechs.ai Partners with ARJ Medical to Advance AI-Driven Neuro and Prostate Imaging in the Middle East

Cortechs.ai and ARJ Medical have partnered to expand access to AI-powered neuro and prostate imaging solutions across the Middle East.
Scroll to Top